Polyethylene Glycol 3350 for Constipation in Pregnancy – AGA Guideline Recommendations
Safety Profile
- The American Gastroenterological Association (AGA) 2024 guidelines state that osmotic laxatives such as polyethylene glycol (PEG) can be administered safely throughout pregnancy because the agent is not systemically absorbed, minimizing fetal exposure. 1
- PEG has an established safety record with no teratogenic concerns, in contrast to stimulant laxatives whose safety data are conflicting and therefore should be avoided. 3
Recommended Treatment Options (AGA Clinical Practice Update 2024)
- Best‑practice advice from the AGA recommends that constipation in pregnant individuals be managed with dietary fiber, lactulose, and PEG‑based laxatives as first‑line pharmacologic choices. 6
First‑Line Non‑Pharmacologic Measures
- Increase dietary fiber to roughly 30 g per day using fruits, vegetables, whole grains, and legumes. 2
- Ensure adequate fluid intake, especially water, to help soften stools. 3
Pharmacologic Options
Bulk‑Forming Agents
- Bulk‑forming agents such as psyllium husk or methylcellulose are considered safe because they are not systemically absorbed. 2
Osmotic Laxatives
- When dietary measures are insufficient, osmotic laxatives—including PEG 3350 and lactulose—may be initiated. 4
Therapies to Avoid
- Stimulant laxatives should be avoided in pregnancy because existing safety data are conflicting. 4
Adverse Effects and Tolerability
- Maternal bloating can occur with excessive fiber intake and with osmotic laxatives such as lactulose, but it is reported less frequently with PEG. 2
Timing of Use
- PEG 3350 may be used safely in any trimester of pregnancy when non‑pharmacologic measures fail to relieve constipation. 1